Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative intratumoral and intramuscular Poly-ICLC (Hiltonol) in stage 2–3 cutaneous melanoma
TCTR20220202004Phase 1Unknown
- Sponsor
- N/A
- Start
- Mar 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of poly iclc in cutaneous melanoma (CM), sponsored by N/A. Primary endpoints: Clinical response and Pathological response. Status: unknown.
02
Drugs
poly iclc
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on TCTR20220202004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220202004.